[Federal Register Volume 81, Number 109 (Tuesday, June 7, 2016)]
[Notices]
[Pages 36650-36651]
[FR Doc No: 2016-13331]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

[Docket No. FAA-2016-4000]

Recommendations for Facilities Realignments To Support Transition
to NextGen as Part of Section 804 of the FAA Modernization and Reform
Act of 2012--Part 2; Request for Comments

AGENCY: Federal Aviation Administration (FAA), Department of
Transportation (DOT).

ACTION: Notice of availability; request for comments.

-----------------------------------------------------------------------

SUMMARY: This document announces the availability of the FAA National
Facilities Realignment and Consolidation Report, Part 2. The report was
developed in response to Section 804 of the FAA Modernization and
Reform Act of 2012 (Pub. L. 112-95). The report and recommendations
contained therein have been developed collaboratively with the National
Air Traffic Controllers Association (NATCA) and the Professional
Aviation Safety Specialists (PASS) labor unions and with input from
stakeholders. The FAA seeks comments on this report.

DATES: Send comments on or before July 22, 2016.

ADDRESSES: Send comments identified by docket number FAA-2016-4000
using any of the following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov and follow the online instructions for sending your
comments electronically.
     Mail: Send comments to Docket Operations, M-30; U.S.
Department of Transportation (DOT), 1200 New Jersey Avenue SE., Room
W12-140, West Building Ground Floor, Washington, DC 20590-0001.
     Hand Delivery or Courier: Take comments to Docket
Operations in Room W12-140 of the West Building Ground Floor at 1200
New Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays.
     Fax: Fax comments to Docket Operations at<PHONE_NUMBER>.
    Privacy: The FAA will post all comments it receives, without
change, to http://www.regulations.gov, including any personal
information the commenter provides. Using the search function of the
docket Web site, anyone can find and read the electronic form of all
comments received into any FAA dockets, including name of the
individual sending the comment (or signing the comment for an
association, business, labor union, etc.). DOT's complete Privacy Act
Statement can be found in the Federal Register published on April 11,
2000 (65 FR 19477-19478), as well as at http://DocketsInfo.dot.gov.
    Docket: Background documents or comments received may be read at
http://www.regulations.gov at any time. Follow the online instructions
for accessing the docket or visit Docket Operations in Room W12-140 of
the West Building Ground Floor at 1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays.

FOR FURTHER INFORMATION CONTACT: Jim Pasto, Federal Aviation
Administration, 800 Independence Avenue SW., Washington, DC 20591;
email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

Background

    Section 804 of the FAA Modernization and Reform Act of 2012 (Public
Law 112-95) requires the FAA to develop a plan for realigning and
consolidating facilities in an effort to support the transition to
NextGen and reduce costs where such cost reductions can be implemented
without adversely affecting safety. To address Section 804
requirements, the FAA formed a collaborative workgroup of
representatives from the FAA and NATCA and PASS labor unions to develop
a comprehensive process to analyze different realignment and
consolidation scenarios. The collaborative process takes into account
the following factors and criteria when prioritizing facilities for
realignment analysis: NextGen readiness; the Terminal Automation
program schedule; operational and airspace factors; existing facility
conditions and workforce impacts; industry stakeholder input; costs and
benefits associated with each potential realignment alternative;
facilities and engineering planning and priorities; and employee career
development.
    The collaborative workgroup developed the guiding principles and
criteria for evaluating existing Terminal Radar Approach Control
(TRACON) operations. The principles support the goals of developing
operationally viable realignment and consolidation scenarios, capturing
recommendations, and outlining next steps. The workgroup has developed
a repeatable and defensible four-step process to evaluate facility
TRACON operations and prioritize for analysis; determine an initial set
of realignment scenarios and a set of alternatives for each scenario;
collect facility and operational data and document system requirements;
document facility, equipment, infrastructure, operational and safety
data; capture qualitative workforce considerations, including training,
transition, facility, and potential workforce impacts of potential
realignments; consider potential impacts on operations, airspace
modifications, route/fixes changes, arrival/departure procedures,
intra/inter-facility coordination, and pilot community interaction;
collect and consider industry stakeholder input; quantify benefits and
cost of potential realignments; and develop a recommendation for each
realignment scenario. The recommendations contained in the report
entitled ``FAA National Facilities Realignment and Consolidation
Report, Part 2'' primarily consist of legacy sites. Legacy sites are
those sites that were determined by the FAA to be realigned prior to
enactment of Section 804 of the FAA Modernization and Reform Act of
2012 and workgroup establishment. A copy of this report has been placed
in the docket for this notice. The docket may be accessed at http://www.regulations.gov. A copy of the report has also been made available
on the FAA's Web site at http://www.faa.gov/regulations_policies/rulemaking/recently_published/.
    The realignment recommendations outlined in the Part 2 report are
the result of a collaborative process that involved a multi-
disciplinary team of FAA management, labor, field facilities, finance,
and subject matter experts. The Section 804 process serves as a stable
foundation for future realignment analyses and recommendations. The
process aims to maximize operational, administrative, and maintenance
efficiencies, support transition to NextGen, and deliver the highest
value to stakeholders.
    The FAA is requesting comments on this report pursuant to Section
804 of the FAA Modernization and Reform Act of 2012. The agency will
consider all comments received on or before July 22, 2016. Following a
60-day comment review period, the final report along with public
comments will be submitted to Congress. The FAA continues to analyze
data collected from facilities across the United States and evaluate
possible realignment scenarios.

    Issued in Washington, DC, on May 31, 2016.
Jim Pasto,
Terminal Facilities Execution Team, Implementation Manager, Federal
Aviation Administration.
[FR Doc. 2016-13331 Filed 6-6-16; 8:45 am]
 BILLING CODE 4910-13-P


[Federal Register: December 26, 2007 (Volume 72, Number 246)]
[Notices]
[Page 73052-73053]
[DOCID:fr26de07-109]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56977; File No. SR-CBOE-2007-148]

Self-Regulatory Organizations; Chicago Board Options Exchange,
Incorporated; Notice of Filing and Immediate Effectiveness of a
Proposed Rule Change To Amend its Equity Options Obvious Error Rule

December 18, 2007.
    Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934
(``Act'') \1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on December 14, 2007, the Chicago Board Options Exchange, Incorporated
(``CBOE'' or ``Exchange'') filed with the Securities and Exchange
Commission (``Commission'') the proposed rule change as described in
Items I, II, and III below, which Items have been substantially
prepared by the Exchange. CBOE has designated this proposal as one
concerned solely with the administration of the Exchange under section
19(b)(3)(A)(iii) of the Act \3\ and Rule 19b-4(f)(3) thereunder,\4\
which renders the proposal effective upon filing with the Commission.
The Commission is publishing this notice to solicit comments on the
proposed rule change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A)(iii).
    \4\ 17 CFR 240.19b-4(f)(2).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to amend CBOE Rule 6.25, which is the
Exchange's rule applicable to the nullification and adjustment of
equity options transactions. The text of the proposed rule change is
available at the Exchange, the Commission's Public Reference Room, and
http://www.cboe.com.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of, and basis for, the proposed rule change, and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. CBOE has substantially prepared summaries, set forth in
sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    Under CBOE's equity obvious error rule, an Obvious Error Panel may
be formed to review decisions made by Trading Officials under the rule.
The Obvious Error Panel is currently comprised of at least one Trading
Floor Liaison (``TFL'') staff member and four Exchange members. The
purpose of the proposed rule change is to replace the reference to the
``TFL'' staff with a reference to the ``Exchange's staff designated to
perform Obvious Error Panel functions.'' The Exchange is proposing to
make this change because it recently determined to reassign the Obvious
Error Panel function from the CBOE TFL group to a group of designated
Exchange personnel within CBOE's market control center. In trying to
accommodate the reassignment of these particular TFL functions, the
Exchange believes a better approach than specifically referencing a
particular Exchange staff group is to reference the ``Exchange's staff
designated to perform'' the particular function. In this way, the
Exchange will have the flexibility to delegate the authorities under
the obvious error rules to the appropriate Exchange staff and will not
have to make a rule change merely, for instance, to accommodate a
future change in the title of a staff group or to accommodate the
reassignment of the authority to another staff group. The Exchange
believes that because the authority exercised by Exchange staff is
delegated pursuant to Exchange rules, the title of the particular group
exercising their authority should not be relevant.\5\
---------------------------------------------------------------------------

    \5\ The Exchange recently made a similar change when it deleted
specific references to TFLs in its obvious error rules in order to
accommodate the reassignment of Trading Official functions under the
rules from the TFL group to a group of designated Exchange personnel
within CBOE's market control center. See Securities Exchange Act
Release No. 56494 (September 21, 2007), 72 FR 55264 (September 28,
2007) (SR-CBOE-2007-110). Under the revised rules, ``Trading
Officials'' now means two Exchange members designated as Floor
Officials and one member of the Exchange's staff designated to
perform Trading Official functions. See CBOE Rules 6.25, Commentary
02 and 24.16, Commentary 02.

---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that the proposed rule change is consistent
with section 6(b) of the Act \6\ in general, and furthers the
objectives of section 6(b)(5) of the Act \7\ in particular, in that it
is designed to promote just and equitable principles of trade, foster
cooperation among persons engaged in facilitating securities
transactions, and protect investors and the public interest. The
Exchange believes that this proposal complies with the Act because the
Exchange is amending its rules to update and/or generalize references
to certain Exchange staff in order to facilitate compliance.
---------------------------------------------------------------------------

    \6\ 15 U.S.C. 78f(b).
    \7\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    The Exchange neither solicited nor received comments with respect
to the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    The foregoing proposed rule change has been designated as concerned
solely with the administration of the Exchange pursuant to section
19(b)(3)(A)(iii) of the Act \8\ and Rule 19b-4(f)(3) \9\ thereunder.
Accordingly, the proposal will take effect upon filing with the
Commission. At any time within 60 days of the filing of such proposed
rule change, the Commission may summarily abrogate such proposed rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act.
---------------------------------------------------------------------------

    \8\ 15 U.S.C. 78s(b)(3)(A)(iii).
    \9\ 17 CFR 240.19b-4(f)(3).
---------------------------------------------------------------------------

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml.
); or     Send an e-mail to<EMAIL_ADDRESS>Please include

File Number SR-CBOE-2007-148 on the subject line.

Paper Comments

     Send paper comments in triplicate to Nancy M. Morris,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.
All submissions should refer to File Number SR-CBOE-2007-148. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml
). Copies of the submission, all subsequent amendments, all

written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for inspection and
copying in the Commission's Public Reference Room, 100 F Street, NE.,
Washington, DC 20549, on official business days between the hours of 10
a.m. and 3 p.m. Copies of such filing also will be available for
inspection and copying at the principal office of the Exchange. All
comments received will be posted without change; the Commission does
not edit personal identifying information from submissions. You should
submit only information that you wish to make available publicly. All
submissions should refer to File Number SR-CBOE-2007-148 and should be
submitted on or before January 16, 2008.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\10\
---------------------------------------------------------------------------

    \10\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Deputy Secretary.
 [FR Doc. E7-24890 Filed 12-21-07; 8:45 am]

BILLING CODE 8011-01-P


[Federal Register Volume 82, Number 235 (Friday, December 8, 2017)]
[Notices]
[Pages 57993-57994]
[FR Doc No: 2017-26469]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-D-0508]

Registration and Product Listing for Owners and Operators of
Domestic Tobacco Product Establishments; Guidance for Industry;
Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a revised guidance for industry entitled ``Registration
and Product Listing for Owners and Operators of Domestic Tobacco
Product Establishments.'' This guidance is intended to assist persons
making tobacco product establishment registration and product listing
submissions to FDA.

DATES: The announcement of the guidance is published in the Federal
Register on December 8, 2017.

ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2009-D-0508 for ``Registration and Product Listing for Owners and
Operators of Domestic Tobacco Product Establishments.'' Received
comments will be placed in the docket and, except for those submitted
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including

the claimed confidential information, in its consideration of comments.
The second copy, which will have the claimed confidential information
redacted/blacked out, will be available for public viewing and posted
on https://www.regulations.gov. Submit both copies to the Dockets
Management Staff. If you do not wish your name and contact information
to be made publicly available, you can provide this information on the
cover sheet and not in the body of your comments and you must identify
this information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    Submit written requests for single copies of this guidance to the
Center for Tobacco Products, Food and Drug Administration, Document
Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G335, Silver
Spring, MD 20993-0002. Send one self-addressed adhesive label to assist
that office in processing your request or include a Fax number to which
the guidance document may be sent. See the SUPPLEMENTARY INFORMATION
section for information on electronic access to the guidance.

FOR FURTHER INFORMATION CONTACT: Matthew Brenner, Center for Tobacco
Products, Food and Drug Administration, Document Control Center, 10903
New Hampshire Ave., Bldg. 71, Rm. G335, Silver Spring, MD 20993-0002,
1-877-287-1373, email: [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a revised guidance for
industry entitled ``Registration and Product Listing for Owners and
Operators of Domestic Tobacco Product Establishments.'' This guidance
is intended to assist persons making tobacco product establishment
registration and product listing submissions to FDA. We are issuing
this guidance consistent with our good guidance practices (GGP)
regulation (Sec.  10.115 (21 CFR 10.115)). We are implementing this
guidance without prior public comment because we have determined that
prior public participation is not feasible or appropriate (Sec.
10.115(g)(2)). We made this determination given the upcoming deadline
for product listing information updates for owners and operators of
tobacco product manufacturing establishments. In addition, the
compliance policy for certain product listing information updates set
forth in this revised guidance presents a policy to limit submissions
consistent with the public health. Although this guidance document is
immediately in effect, it remains subject to comment in accordance with
FDA's GGP regulation.
    This revised guidance describes the compliance policy for product
listing information updates for deemed tobacco products for persons who
owned or operated domestic manufacturing establishments engaged in the
manufacture of deemed products prior to August 8, 2016, and continued
to own or operate such establishment(s) on or after August 8, 2016.
With respect to the deemed tobacco products listing requirement, FDA
does not intend to enforce the requirement for persons who own or
operate domestic manufacturing establishments engaged in the
manufacture of deemed tobacco products to update product listing
information during the month of December 2017 provided they registered
and listed their products by October 12, 2017.\1\ As a result,
registrants of deemed products would update their product listing by
June 30, 2018, and complete their next annual registration by December
31, 2018. If an establishment is engaged in the manufacture of both
deemed tobacco products and tobacco products originally regulated under
the Federal Food, Drug, and Cosmetic Act (the FD&C Act), FDA intends to
enforce the registration and product listing information requirements
for tobacco products originally regulated under the FD&C Act.
---------------------------------------------------------------------------

    \1\ Registration by such persons by October 12, 2017, satisfies
the requirement in section 905(b) of the FD&C Act that such persons
register their establishments annually on or before December 31,
2017.
---------------------------------------------------------------------------

    Owners or operators of establishments engaged in the manufacture of
deemed products as of August 8, 2016, were first required to register
and submit deemed product listing information under section 905 of the
FD&C Act (21 U.S.C. 387e) by December 31, 2016. However, in a guidance
issued in September 2017, FDA announced that it does not intend to
enforce these requirements with respect to deemed products provided the
registration and product listing submissions were received by FDA on or
before October 12, 2017.

II. Significance of Guidance

    This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on registration and product listing for owners
and operators of domestic tobacco product establishments. It does not
establish any rights for any person and is not binding on FDA or the
public. You can use an alternative approach if it satisfies the
requirements of the applicable statutes and regulations. This guidance
is not subject to Executive Order 12866.

III. Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in section 905 of the FD&C Act have been
approved under OMB control number 0910-0650.

IV. Electronic Access

    Persons with access to the internet may obtain an electronic
version of the guidance at either https://www.regulations.gov or
https://www.fda.gov/TobaccoProducts/Labeling/RulesRegulationsGuidance/default.htm.

    Dated: December 4, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-26469 Filed 12-7-17; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register: December 3, 2007 (Volume 72, Number 231)]
[Rules and Regulations]
[Page 67841-67843]
[DOCID:fr03de07-2]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2007-28980 Directorate Identifier 2007-CE-071-AD;
Amendment 39-15282; AD 2007-25-01]
RIN 2120-AA64

Airworthiness Directives; Aircraft Industries, a.s. (Type
Certificate No. G24EU Formerly Held by LETECK[Eacute] Z[Aacute]VODY
a.s. and LET Aeronautical Works) Model L-13 Blanik Gliders

AGENCY: Federal Aviation Administration (FAA), Department of
Transportation (DOT).

ACTION: Final Rule.

-----------------------------------------------------------------------

SUMMARY: We are adopting a new airworthiness directive (AD) for the
products listed above. This AD results from mandatory continuing
airworthiness information (MCAI) issued by an aviation authority of
another country to identify and correct an unsafe condition on an
aviation

product. The MCAI describes the unsafe condition as:

    This Airworthiness Directive (AD) is prompted by the discovery
of cracks on L13 BLANIK sailplanes in zones where the forward and
aft control sticks are attached to the connecting rod, designated as
``control bridge'' in the relevant Illustrated Parts Catalogues
(IPC). If left uncorrected, cracks could propagate and lead to
failure of the connecting rod with subsequent loss of control of the
sailplane.

We are issuing this AD to require actions to correct the unsafe
condition on these products.

DATES: This AD becomes effective January 7, 2008.
    On January 7, 2008, the Director of the Federal Register approved
the incorporation by reference of certain publications listed in this
AD.

ADDRESSES: You may examine the AD docket on the Internet at http://www.regulations.gov
 or in person at Document Management Facility, U.S.

Department of Transportation, Docket Operations, M-30, West Building
Ground Floor, Room W12-140, 1200 New Jersey Avenue, SE., Washington, DC
20590.

FOR FURTHER INFORMATION CONTACT: Greg Davison, Glider Program Manager,
FAA, Small Airplane Directorate, 901 Locust, Room 301, Kansas City,
Missouri 64106; telephone:<PHONE_NUMBER>; fax:<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Discussion

    We issued a notice of proposed rulemaking (NPRM) to amend 14 CFR
part 39 to include an AD that would apply to the specified products.
That NPRM was published in the Federal Register on October 4, 2007 (72
FR 56700). That NPRM proposed to correct an unsafe condition for the
specified products. The MCAI states:

    This Airworthiness Directive (AD) is prompted by the discovery
of cracks on L13 BLANIK sailplanes in zones where the forward and
aft control sticks are attached to the connecting rod, designated as
``control bridge'' in the relevant Illustrated Parts Catalogues
(IPC). If left uncorrected, cracks could propagate and lead to
failure of the connecting rod with subsequent loss of control of the
sailplane.
    For the reasons described above, this AD requires an inspection
of the control bridge to detect cracks and replacement, if
necessary. In addition, this AD requires an update of the aircraft
Maintenance Manual (MM) to incorporate repetitive inspections of the
control bridge.

Comments

    We gave the public the opportunity to participate in developing
this AD. We received no comments on the NPRM or on the determination of
the cost to the public.

Conclusion

    We reviewed the available data and determined that air safety and
the public interest require adopting the AD as proposed.

Differences Between This AD and the MCAI or Service Information

    We have reviewed the MCAI and related service information and, in
general, agree with their substance. But we might have found it
necessary to use different words from those in the MCAI to ensure the
AD is clear for U.S. operators and is enforceable. In making these
changes, we do not intend to differ substantively from the information
provided in the MCAI and related service information.
    We might also have required different actions in this AD from those
in the MCAI in order to follow FAA policies. Any such differences are
highlighted in a NOTE within the AD.

Costs of Compliance

    We estimate that this AD will affect 190 products of U.S. registry.
We also estimate that it will take about 2 work-hours per product to
comply with basic requirements of this AD. The average labor rate is
$80 per work-hour.
    Based on these figures, we estimate the cost of this AD to the U.S.
operators to be $30,400 or $160 per product.
    In addition, we estimate that any necessary follow-on actions would
take about 7 work-hours and require parts costing $2,000, for a cost of
$2,560 per product. We have no way of determining the number of
products that may need these actions.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. ``Subtitle VII: Aviation
Programs,'' describes in more detail the scope of the Agency's
authority.
    We are issuing this rulemaking under the authority described in
``Subtitle VII, Part A, Subpart III, Section 44701: General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.

Regulatory Findings

    We determined that this AD will not have federalism implications
under Executive Order 13132. This AD will not have a substantial direct
effect on the States, on the relationship between the national
government and the States, or on the distribution of power and
responsibilities among the various levels of government.
    For the reasons discussed above, I certify this AD:
    (1) Is not a ``significant regulatory action'' under Executive
Order 12866;
    (2) Is not a ``significant rule'' under DOT Regulatory Policies and
Procedures (44 FR 11034, February 26, 1979); and
    (3) Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.
    We prepared a regulatory evaluation of the estimated costs to
comply with this AD and placed it in the AD Docket.

Examining the AD Docket

    You may examine the AD docket on the Internet at http://www.regulations.gov
; or in person at the Docket Management Facility

between 9 a.m. and 5 p.m., Monday through Friday, except Federal
holidays. The AD docket contains the NPRM, the regulatory evaluation,
any comments received, and other information. The street address for
the Docket Office (telephone<PHONE_NUMBER>) is in the ADDRESSES
section. Comments will be available in the AD docket shortly after
receipt.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

 Adoption of the Amendment

0
Accordingly, under the authority delegated to me by the Administrator,
the FAA amends 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

0
2. The FAA amends Sec.  39.13 by adding the following new AD:

2007-25-01 Aircraft Industries, a.s. (Type Certificate No. G24EU
formerly held by Letecke Zavody a.s. and LET

Aeronautical Works): Amendment 39-15282; Docket No. FAA-2007-28980;
Directorate Identifier 2007-CE-071-AD.

Effective Date

    (a) This airworthiness directive (AD) becomes effective January
7, 2008.

Affected ADs

    (b) None.

Applicability

    (c) This AD applies to Model L-13 Blanik gliders, all serial
numbers, certificated in any category.

Subject

    (d) Air Transport Association of America (ATA) Code 27: Flight
Controls.

Reason

    (e) The mandatory continuing airworthiness information (MCAI)
states:
    This Airworthiness Directive (AD) is prompted by the discovery
of cracks on L13 Blanik sailplanes in zones where the forward and
aft control sticks are attached to the connecting rod, designated as
``control bridge'' in the relevant Illustrated Parts Catalogues
(IPC). If left uncorrected, cracks could propagate and lead to
failure of the connecting rod with subsequent loss of control of the
sailplane.
    For the reasons described above, this AD requires an inspection
of the control bridge to detect cracks and replacement, if
necessary. In addition, this AD requires an update of the aircraft
Maintenance Manual (MM) to incorporate repetitive inspections of the
control bridge.

Actions and Compliance

    (f) Unless already done, do the following actions:
    (1) Within the next 3 months after January 7, 2008 (the
effective date of this AD) and repetitively thereafter at intervals
not to exceed 12 months, inspect the control bridge for cracks.
Follow the procedures in LET Aircraft Industries, a.s. Mandatory
Bulletin MB No.: L13 / 105a, dated May 22, 2007, except use a 10X
magnifier and do a dye penetrant inspection following the procedures
in chapter 5, section 5, of FAA Advisory Circular AC 43.13-1B CHG 1,
dated September 27, 2001.
    (2) If cracks are found during any inspection in paragraph
(f)(1) of this AD, before further flight, install a new control
bridge Dwg. No. (part number (P/N)) A740 370 N or Dwg. No. (P/N)
A401 001N following the procedures in LET Aircraft Industries, a.s.
Mandatory Bulletin MB No.: L13 / 105a, dated May 22, 2007.

FAA AD Differences

    Note: This AD differs from the MCAI and/or service information
as follows:

    (1) The service information requires a visual inspection with a
6X magnifier. We are requiring a dye penetrant inspection and a 10X
magnifier to detect cracks that could go undetected using only a 6X
magnifier.
    (2) The MCAI requires updating the maintenance manuals to add
``type A based'' repetitive inspections of the control bridge. Since
the maintenance manual is only one way of establishing a maintenance
program, the only way we can mandate these repetitive inspections is
through an AD action.

Other FAA AD Provisions

    (g) The following provisions also apply to this AD:
    (1) Alternative Methods of Compliance (AMOCs): The Manager,
Standards Office, FAA, has the authority to approve AMOCs for this
AD, if requested using the procedures found in 14 CFR 39.19. Send
information to ATTN: Greg Davison, Glider Program Manager, FAA,
Small Airplane Directorate, 901 Locust, Room 301, Kansas City,
Missouri 64106; telephone:<PHONE_NUMBER>; fax:<PHONE_NUMBER>.
Before using any approved AMOC on any airplane to which the AMOC
applies, notify your appropriate principal inspector (PI) in the FAA
Flight Standards District Office (FSDO), or lacking a PI, your local
FSDO.
    (2) Airworthy Product: For any requirement in this AD to obtain
corrective actions from a manufacturer or other source, use these
actions if they are FAA-approved. Corrective actions are considered
FAA-approved if they are approved by the State of Design Authority
(or their delegated agent). You are required to assure the product
is airworthy before it is returned to service.
    (3) Reporting Requirements: For any reporting requirement in
this AD, under the provisions of the Paperwork Reduction Act (44
U.S.C. 3501 et seq.), the Office of Management and Budget (OMB) has
approved the information collection requirements and has assigned
OMB Control Number 2120-0056.

Related Information

    (h) Refer to MCAI European Aviation Safety Agency (EASA) AD No.
2007-0212, dated August 7, 2007; and LET Aircraft Industries, a.s.
Mandatory Bulletin MB No.: L13 / 105a, dated May 22, 2007, for
related information.

Material Incorporated by Reference

    (i) You must use LET Aircraft Industries, a.s. Mandatory
Bulletin MB No.: L13 / 105a, dated May 22, 2007, to do the actions
required by this AD, unless the AD specifies otherwise.
    (1) The Director of the Federal Register approved the
incorporation by reference of this service information under 5
U.S.C. 552(a) and 1 CFR part 51.
    (2) For service information identified in this AD, contact
Aircraft Industries, a.s., Na Z[aacute]honech 1177, 686 04 Kunovice,
Czech Republic; phone: +420 572 817 660; fax: +420 572 816 112; e-
mail<EMAIL_ADDRESS>    (3) You may review copies at the FAA, Central Region, Office of
the Regional Counsel, 901 Locust, Room 506, Kansas City, Missouri
64106; or at the National Archives and Records Administration
(NARA). For information on the availability of this material at
NARA, call<PHONE_NUMBER>, or go to: http://www.archives.gov/federal-register/cfr/ibr-locations.html
.

    Issued in Kansas City, Missouri, on November 23, 2007.
Steven W. Thompson,
Acting Manager, Small Airplane Directorate, Aircraft Certification
Service.
 [FR Doc. E7-23222 Filed 11-30-07; 8:45 am]

BILLING CODE 4910-13-P


[Federal Register Volume 88, Number 9 (Friday, January 13, 2023)]
[Notices]
[Page 2386]
[FR Doc No: 2023-00604]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Pipeline and Hazardous Materials Safety Administration

Hazardous Materials: Notice of Applications for Special Permits

AGENCY: Pipeline and Hazardous Materials Safety Administration (PHMSA),
DOT.

ACTION: List of applications for modification of special permits.

-----------------------------------------------------------------------

SUMMARY: In accordance with the procedures governing the application
for, and the processing of, special permits from the Department of
Transportation's Hazardous Material Regulations, notice is hereby given
that the Office of Hazardous Materials Safety has received the
application described herein.

DATES: Comments must be received on or before January 30, 2023.

ADDRESSES: Record Center, Pipeline and Hazardous Materials Safety
Administration, U.S. Department of Transportation Washington, DC 20590.
    Comments should refer to the application number and be submitted in
triplicate. If confirmation of receipt of comments is desired, include
a self-addressed stamped postcard showing the special permit number.

FOR FURTHER INFORMATION CONTACT: Donald Burger, Chief, Office of
Hazardous Materials Safety General Approvals and Permits Branch,
Pipeline and Hazardous Materials Safety Administration, U.S. Department
of Transportation, East Building, PHH-13, 1200 New Jersey Avenue
Southeast, Washington, DC 20590-0001,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: Each mode of transportation for which a
particular special permit is requested is indicated by a number in the
``Nature of Application'' portion of the table below as follows: 1--
Motor vehicle, 2--Rail freight, 3--Cargo vessel, 4--Cargo aircraft
only, 5--Passenger-carrying aircraft.
    Copies of the applications are available for inspection in the
Records Center, East Building, PHH-13, 1200 New Jersey Avenue
Southeast, Washington DC or at http://regulations.gov.
    This notice of receipt of applications for special permit is
published in accordance with part 107 of the Federal hazardous
materials transportation law (49 U.S.C. 5117(b); 49 CFR 1.53(b)).

    Issued in Washington, DC, on January 9, 2023.
Donald P. Burger,
Chief, General Approvals and Permits Branch.

----------------------------------------------------------------------------------------------------------------
                                                                                Nature of the special permits
       Application No.                Applicant           Regulation(s) affected              thereof
----------------------------------------------------------------------------------------------------------------
                                              Special Permits Data
----------------------------------------------------------------------------------------------------------------
9998-M......................  Accumulators, Inc........  173.302(a)..............  To modify the special permit
                                                                                to authorize additional
                                                                                accumulators. (modes 1, 2,
                                                                                3, 4).
11771-M.....................  Phillips 66 Pipeline LLC.  172.302(c),               To modify the special permit
                                                          173.31(d)(1)(ii),         to authorize DOT 117R rail
                                                          173.31(d)(1)(iv),         cars. (mode 2).
                                                          173.31(d)(1)(vi),
                                                          174.67(b), 174.67(c).
16572-M.....................  Samsung Austin             173.158(f)..............  To modify the special permit
                               Semiconductor, L.L.C..                               to authorize a Division 5.1
                                                                                subsidiary hazard for the
                                                                                hazardous material. (mode
                                                                                1).
20493-M.....................  Tesla, Inc...............  172.101(j)..............  To modify the special permit
                                                                                to authorize additional
                                                                                lithium ion batteries. (mode
                                                                                4).
20851-M.....................  Call2Recycle, Inc........  172.600, 172.200,         To modify the special permit
                                                          172.700(a).               to authorize transportation
                                                                                other than that for
                                                                                recycling. (modes 1,2).
21163-M.....................  United Initiators, Inc...  178.345-10(b)(1)........  To modify the special permit
                                                                                to authorize additional
                                                                                hazardous materials. (mode
                                                                                1).
----------------------------------------------------------------------------------------------------------------

[FR Doc. 2023-00604 Filed 1-12-23; 8:45 am]
BILLING CODE 4910-60-P


[Federal Register Volume 83, Number 221 (Thursday, November 15, 2018)]
[Notices]
[Pages 57528-57529]
[FR Doc No: 2018-24875]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Notice of Intent To Rule on Request To Release Airport Property

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of intent to rule on request to release airport property
at the St. Louis Lambert International Airport (STL), St. Louis,
Missouri.

-----------------------------------------------------------------------

SUMMARY: The FAA proposes to rule and invites public comment on the
release of land at the St. Louis Lambert International Airport, St.
Louis, Missouri, under the provisions of 49 U.S.C. 47107(h)(2).

DATES: Comments must be received on or before December 17, 2018.

ADDRESSES:
    Comments on this application may be mailed or delivered to the FAA
at the following address: Lynn D. Martin, Airports Compliance
Specialist, Federal Aviation Administration, Airports Division, ACE-
610C, 901 Locust, Room 364, Kansas City, MO 64106.
    In addition, one copy of any comments submitted to the FAA must be
mailed or delivered to: Dana Ryan, Planning Manager, St. Louis Lambert
International Airport, 10701 Lambert International Blvd., St. Louis, MO
3145-0212,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Lynn D. Martin, Airports Compliance
Specialist, Federal Aviation Administration, Airports Division, ACE-
610C, 901 Locust, Room 364, Kansas City, MO 64106,<PHONE_NUMBER>,
[email protected].
    The request to release property may be reviewed, by appointment, in
person at this same location.

SUPPLEMENTARY INFORMATION: The FAA invites public comment on the
request to release approximately 1.389 acres of airport property, at
the St. Louis Lambert International Airport (STL) under the provisions
of 49 U.S.C. 47107(h)(2). On June 13, 2018, the Director of Airports
for the City of St. Louis, MO requested from the FAA that approximately
1.389 acres of property, be released for sale to Union Electric

(dba Ameron Missouri) for use as sub-station. On October 22, 2018, the
FAA determined that the request to release property at the St. Louis
Lambert International Airport (STL) submitted by the Sponsor meets the
procedural requirements of the Federal Aviation Administration and the
release of the property does not and will not impact future aviation
needs at the airport. The FAA may approve the request, in whole or in
part, no sooner than thirty days after the publication of this Notice.
    The following is a brief overview of the request:
    St. Louis Lambert International Airport (STL) is proposing the
release of two parcels, one parcel on Monroe Avenue contains 0.826
acres and Parcel 2 on Jefferson Avenue containing 0.563 acres for a
total containing 1.389 acres. The release of land is necessary to
comply with Federal Aviation Administration Grant Assurances that do
not allow federally acquired airport property to be used for non-
aviation purposes. The sale of the subject property will result in the
land at the St. Louis Lambert International Airport (STL) being changed
from aeronautical to non-aeronautical use and release the lands from
the conditions of the Airport Improvement Program Grant Agreement Grant
Assurances. In accordance with 49 U.S.C. 47107(c)(2)(B)(i) and (iii),
the airport will receive fair market value for the property, which will
be subsequently reinvested in another eligible airport improvement
project for aviation at the St. Louis Lambert International Airport.
    In addition, any person may, upon appointment and request, inspect
the application, notice and other documents determined by the FAA to be
related to the application in person at the St. Louis Lambert
International Airport.

    Issued in Kansas City, MO, on November 5, 2018.
Ed Hyatt,
Acting Director, Airports Division.
[FR Doc. 2018-24875 Filed 11-14-18; 8:45 am]
 BILLING CODE 4910-13-P


[Federal Register Volume 81, Number 68 (Friday, April 8, 2016)]
[Notices]
[Page 20629]
[FR Doc No: 2016-08072]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Effectiveness of Exempt Wholesale Generator Status

Frontier Windpower, LLC.................  EG16-33-000
CPV Towantic, LLC.......................  EG16-34-000
CPV Valley, LLC.........................  EG16-35-000
Kingbird Solar A, LLC...................  EG16-36-000
Kingbird Solar B, LLC...................  EG16-37-000
Innovative Solar 43, LLC................  EG16-38-000
Bethel Wind Farm LLC....................  EG16-39-000
Tenaska Pennsylvania Partners, LLC......  EG16-40-000
Horse Creek Wind, LLC...................  EG16-41-000

    Take notice that during the month of March 2016, the status of the
above-captioned entities as Exempt Wholesale Generators became
effective by operation of the Commission's regulations. 18 CFR
366.7(a).

    Dated: April 4, 2016.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2016-08072 Filed 4-7-16; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register: September 19, 2007 (Volume 72, Number 181)]
[Notices]
[Page 53548-53549]
[DOCID:fr19se07-56]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP07-446-000]

Natural Gas Pipeline Company of America; Notice of Request Under
Blanket Authorization

September 12, 2007.
    Take notice that on September 6, 2007, Natural Gas Pipeline Company
of America (Natural), 747 East 22nd Street, Lombard, Illinois 60148,
filed in Docket No. CP07-446-000, a prior notice request pursuant to
sections 157.205 and 157.210 of the Federal Energy Regulatory
Commission's regulations under the Natural Gas Act for authorization to
increase the horsepower of one of the existing gas turbine compressor
units at Compressor Station 342 (CS 342), located in Cameron Parish,
Louisiana, all as more fully set forth in the application, which is on
file with the Commission and open to public inspection. The filing may
also be viewed on the Web at http://www.ferc.gov using the ``eLibrary''

link. Enter the docket number excluding the last three digits in the
docket number field to access the document. For assistance, contact
FERC at<EMAIL_ADDRESS>or call toll-free,<PHONE_NUMBER> or
TYY,<PHONE_NUMBER>.
    Natural states that in order to create a degree of operational
flexibility, compressor Unit 5 at CS 342 will be upgraded from
4,200 horsepower to 5,280 horsepower at the same time it will be
undergoing a routine overhaul. Natural asserts that the increase in
horsepower will not increase mainline capacity nor will it change the
design throughput capacity of CS 342. Natural estimates the cost of
construction to be $545,000.
    Any questions regarding the application should be directed to Bruce
H. Newsome, Vice President, Natural Gas Pipeline Company of America,
747 East 22nd Street, Lombard, Illinois 60148-5072, or call at (630)
691-3526.
    Any person or the Commission's Staff may, within 60 days after the
issuance of the instant notice by the Commission, file pursuant to Rule
214 of the Commission's Procedural Rules (18 CFR 385.214) a motion to
intervene or notice of intervention and, pursuant to section 157.205 of
the Commission's Regulations under the Natural Gas Act (NGA) (18 CFR
157.205) a protest to the request. If no protest is filed within the
time allowed therefore, the proposed activity shall be deemed to be
authorized effective the day after the time allowed for protest. If a
protest is filed and not withdrawn within 30 days after the time
allowed for filing a protest, the instant request shall be treated as
an application for authorization pursuant to Section 7 of the NGA.
    The Commission strongly encourages electronic filings of comments,
protests, and interventions via the Internet in lieu of paper. See 18
CFR 385.2001(a) (1) (iii) and the instructions on the

Commission's Web site (http://www.ferc.gov) under the ``e-Filing'' link.

Kimberly D. Bose,
Secretary.
[FR Doc. E7-18445 Filed 9-18-07; 8:45 am]

BILLING CODE 6717-01-P


<EPA REGISTRATION DIVISION COMPANY NOTICE OF FILING FOR PESTICIDE PETITIONS PUBLISHED IN THE FEDERAL REGISTER  >

<EPA Registration Division contact: Shaja Joyner,<PHONE_NUMBER>>

<INSTRUCTIONS:  Please utilize this outline in preparing the pesticide petition.  In cases where the outline element does not apply, please insert “NA-Remove” and maintain the outline. Please do not change the margins, font, or format in your pesticide petition. Simply replace the instructions that appear in green, i.e., “[insert company name],” with the information specific to your action.>

<TEMPLATE:>

<  SEQ CHAPTER \h \r 1 ISK Biosciences Corporation>

<[Insert petition number]>

<	EPA has received a pesticide petition ([insert petition number]) from ISK Biosciences Corporation, 7470 Auburn Road, Suite A, Concord, Ohio, 44077, proposing, pursuant to section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a(d), to amend 40 CFR part 180 by establishing a tolerance for residues of the fungicide pyriofenone, (5-chloro-2-methoxy-4-methyl-3-pyridinyl)(2,3,4-trimethoxy-6-methylpheny l)methanone, in or on the raw agricultural commodity grape at 0.2 parts per million (ppm).  EPA has determined that the petition contains data or information regarding the elements set forth in section 408 (d)(2) of  FDDCA; however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data supports granting of the petition. Additional data may be needed before EPA rules on the petition.>

<A. Residue Chemistry>

<Plant metabolism. The metabolism of pyriofenone as well as the nature of the residues in plants is adequately understood for the purposes of this tolerance.  Metabolism studies were conducted with three diverse crops, grapes, wheat and tomatoes.  All three crops showed a similar pattern of metabolism with unchanged pyriofenone remaining on the plant surfaces.  The metabolism of pyriofenone in plants results in a large number of fragments in only trace amounts.  Hence, parent pyriofenone is the only residue of concern.

>

<Analytical method. A practical analytical method for Pyriofenone using Liquid Chromatography-MS/MS is available for analysis of grapes.  This method has been confirmed through independent laboratory validation and is available for enforcement purposes.>

<Magnitude of residues. Seventeen grape trials were conducted in Germany (4 trials), Northern France (4 trials), southern France (4 trials), Spain (3 trials) and Italy (2 trials).  These studies cover a wide range of geographies with diverse climates and growing conditions, as well as various cultural practices.  The residue values reported gave results which lead to a proposed tolerance of 0.20 ppm.

In four trials, samples were processed into juice, wine and raisins.  There was no concentration of pyriofenone in grape juice, wine, or raisins.  Residues in raisins seen during processing trials were considered to reflect water loss during the drying process used to produce them and are as expected.

>

<B. Toxicological Profile

The proposed tolerance for pyriofenone is for an imported commodity only.  The acute oral toxicity and acute neurotoxicity studies are the only studies required to evaluate acute toxicity. Subchronic dermal and inhalation studies are not required because residential and occupational risk assessments are not necessary to set a tolerance on an imported commodity.>

<1. 	Acute toxicity.  Pyriofenone exhibits low oral acute toxicity. The oral LD50 is greater than 2000 mg/kg. Since this petition is for an import tolerance, oral toxicity data sufficiently assesses the risk of acute exposure for this use.

In an acute neurotoxicity study, pyriofenone was administered by oral gavage to groups of CD rats at doses up to 2000 mg/kg. The animals were observed for 14 days.  A single oral administration of pyriofenone at doses up to 2000 mg/kg, the maximum dose required by the guidelines to which the study was designed, resulted in minimal, transient change and there was no evidence of any neurological effect.  Consequently, 2000 mg/kg was considered to be the NOEL.

>

<2. Genotoxicity. The genotoxic potential of pyriofenone has been assessed as negative by several in vitro and in vivo mutagenicity studies. Pyriofenone did not elicit a genotoxic response in any of the studies conducted.

>

<3. Reproductive and developmental toxicity. Results from a two-generation study indicate that pyriofenone is not a reproductive toxicant. The dietary concentrations for the study were 0, 150, 1000 and 5000 ppm. The NOEL for systemic toxicity was 1000 ppm (equivalent to 64.1 and 79.2 mg/kg/day, respectively for P males and females and 76.8 and 84.4 mg/kg/day for F1 males and females). The NOEL for reproductive toxicity was 5000 ppm (equivalent to 334 and 395 mg/kg/day for P males and females, respectively and 393 and 434 mg/kg/day for F1 males and females).

Results from   SEQ CHAPTER \h \r 1 developmental studies in rats and rabbits provided no indication of teratogenic effects for fetuses of either species and no evidence of developmental effects in the absence of maternal toxicity. For the rat teratology study, doses of 0, 30, 300 or 1000 mg/kg bwt/day were administered between Days 6 and 19 of gestation. The NOEL for maternal toxicity was 30 mg/kg bwt/day.  The NOEL for developmental toxicity was 1000 mg/kg bwt/day, the highest dose tested. Pyriofenone technical was not teratogenic to rats.  For the rabbit teratology study, doses of 0, 30, 100, or 300 mg/kg bwt/day were administered between Days 6 and 27 of gestation. The NOEL for maternal toxicity was 100 mg/kg bwt/day.  The NOEL for developmental toxicity was 300 mg/kg bwt/day, the highest dose tested. Pyriofenone technical was not teratogenic to rabbits.

4. Subchronic toxicity. Short-term (28-day) toxicity studies were conducted in rats and dogs.  Doses evaluated in the rat study were 0, 300, 3000, 10,000, and 20,000 ppm.  The NOEL was 300 ppm (equivalent to 24.2 and 26.1 mg/kg bwt/day, respectively for males and females). Effects observed at 3000 ppm included hyaline droplets in the kidney proximal tubular cells, changes in the blood plasma and increased liver weights for males and increased liver weights, increased kidney weights and hepatocyte hypertrophy in one animal for females.  Doses evaluated in the dog study were 0, 500, 1500, 5000, and 15,000 ppm.  The NOEL was 5000 ppm for males (equivalent to 144 mg/kg bwt/day) and 1500 ppm (equivalent to 47.5 mg/kg bwt/day) for females. In addition, subchronic (90-day) feeding studies were conducted in rats, mice, and dogs. Doses evaluated in the rat study were 0, 300, 1000, 2500, and 5000 ppm.  The NOEL was 1000 ppm (equivalent to 60.5 and 69.0 mg/kg bwt/day, respectively for males and females). Effects observed at 2500 ppm included high plasma protein, albumin, calcium, low chloride, and increased liver, kidney and cecum weights.  In females at 2500 ppm, increased activated partial thromboplastin time and globulin, and increased liver, kidney and cecum weights were observed. Doses evaluated in the mouse study were 0, 300, 1000, 300, and 7000 ppm.  The NOEL was 1000 ppm (equivalent to 176 mg/kg bwt/day) for males and 300 ppm (equivalent to 61.0 mg/kg bwt/day) for females. Effects included increased liver weights and the presence of periportal hypertrophy in males at 3000 ppm and and increased liver weight observed in females at 1000 ppm. Doses evaluated in the dog study were 0, 500, 3000 and 25,000 ppm in males and 0, 500, 3000 and 15,000 ppm in females.  The NOEL was 3000 ppm (equivalent to 90.3 and 89.8 mg/kg bwt/day, respectively for males and females). At the high doses, effects included decreased weight gain and food intake as well as increased kidney weights in males,  and progressive increase of alkaline phosphatase in both sexes.

>

<5. Chronic toxicity. An 18-month oncogenicity study was conducted in mice with dietary concentrations of 0, 600, 1800 and 5400 ppm for males and 0, 300, 1000, and 3000 ppm for females.    The systemic NOEL was 600 ppm (77.6 mg/kg bwt/day) for males based on non-neoplastic changes in the kidney and liver. The systemic NOEL was 1000 ppm (167 mg/kg bwt/day) for females based on reduced body weights and food consumption. There was no evidence of carcinogenicity.

A 2-year chronic toxicity/carcinogenicity study was conducted in rats with dietary concentrations of 0, 200, 1000 and 5000 ppm technical pyriofenone.  The systemic NOEL was 1000 ppm (36.4 mg/kg bwt/day) for males based on reduced body weight gains and non-neoplastic changes in the kidney, liver, and mesenteric lymph nodes. The systemic NOEL was 200 ppm (9.13 mg/kg bwt/day) for females based on reduced body weight and non-neoplastic changes in the kidney. There was no evidence of carcinogenicity.

A 52-week chronic toxicity study was conducted in dogs with dietary concentrations of 0, 500, 3000 and 25,000 ppm for males and 0, 500, 3000, and 15,000 ppm for females.  The NOEL was 3000 ppm (83.5 and 86.2 mg/kg bwt/day for males and females, respectively). The LOEL was 25,000 ppm (701 mg/kg bwt/day) for males and 15,000 ppm (448 mg/kg bwt/day) for females based decreased weight gain, decreased food intake, and increased kidney weights observed for the males and progressive increase of alkaline phosphatase observed in both sexes.

>

<6. Animal metabolism. The metabolism of pyriofenone in rats and goats is adequately understood. Pyriofenone is rapidly excreted in the urine and feces and was extensively metabolized to a number of components through a number of metabolic pathways including glucuronidation. There are no significant qualitative differences between rat and ruminant metabolic pathways.>

<7. 	Metabolite toxicology. No toxicologically significant metabolites were detected in plant or animal metabolism studies. The residue of concern for tolerance setting purposes is the parent compound. Consequently, there is no additional concern for toxicity of metabolites.

>

<8. 	Endocrine disruption. The submitted studies include evaluation of the potential effects on reproduction and development and an evaluation of the pathology of the endocrine organs following short or long-term exposure. The data demonstrate no treatment-related effects on the endocrine system.

≥1690mg/kg bwt/day). Dietary doses up to 7000 ppm were evaluated in the mouse study.  There was no effect on the immune system at any dose tested.  The NOEL was greater than 7000 ppm (≥1270mg/kg bwt/day). >

<C. Aggregate Exposure>

<1. Dietary exposure. Exposure assessments were conducted to evaluate the potential risk due to dietary exposure of the U.S. population to residues of pyriofenone.

For acute dietary exposure, an Acute Reference Dose (aRfD) is not identified for Pyriofenone since there was no evidence of initial acute effects in the acute oral or short-term toxicity studies, or the developmental toxicity studies in rats and rabbits.  Furthermore, effects in the acute neurotoxicity study were seen only at the limit dose level of 2000 mg/kg/day.  No initial acute effects were seen in the 90-day neurotoxicity study.

For chronic dietary exposure, the chronic reference dose (cRfD) is 0.106 mg/kg bwt/day, based on the NOAEL from the rat combined chronic toxicity/carcinogenicity study (10.6 mg/kg bwt/day) and dividing by an uncertainty factor of 100.  The chronic population adjusted dose (cPAD) is also 0.106 mg/kg bwt/day since the FQPA safety factor is anticipated to be 1 for pyriofenone.

>

<	i. Food. Tier 1 chronic dietary exposure analyses were conducted for pyriofenone in/on grapes to determine the exposure contribution of this commodity to the diet and to ascertain the chronic risk potential.  The exposure estimates were based on the proposed tolerance level residues, average processing factors and a market share of 100% crop treated as a conservative assumption. The consumption data were from the USDA’s CSFII (1994 through 1996 and 1998) continuing survey of food intake using Exponent's Dietary Exposure Evaluation Module (DEEM-FCID) software, version 2.16.

Using all of the worst case exposure scenarios listed above, the Tier 1 chronic dietary exposure estimates resulted in an estimated exposure for the general U.S. population of 0.000130 mg/kg bwt/day.  This exposure corresponds to 0.1% of the cPAD of 0.106 mg/kg bwt/day.  The highest exposure estimate calculated was for the subgroup children, 1-2 years.  This exposure was determined to be 0.000753 mg/kg bwt/day (0.7% of the cPAD).  The chronic dietary exposure analysis is summarized in the table below.

Population	Exposure Estimate	% of cPAD

Subgroup	(mg/kg body wt/day)

U.S. Population	0.000130	0.1

All Infants (< 1 year old)	0.000209	0.2

Children (1-2 years old)	0.000753	0.7

Children (3-5 years old)	0.000456	0.4

Children (6-12 years old)	0.000171	0.2

Youth (13-19 years old)	0.000062	0.1

Females (13-49 years old)	0.000078	0.1

Adults (20-49 years old)	0.000092	0.1

Adults (50+ years old)	0.000083	0.1

It can be concluded that long-term dietary exposure to pyriofenone through residues on treated grapes should not be of cause for concern.

>

<	ii. Drinking water. Pyriofenone is proposed for use only on an imported commodity (grape), therefore the only anticipated exposure route for the US population is by dietary (food) exposure.  With no proposed US registration, there will be no pyriofenone residues in surface or ground water that would be used for drinking water.

>

<	2. Non-dietary exposure. The proposed use for pyriofenone is for an imported commodity (grape).  The only anticipated exposure route for the US population is via the diet (food only). Therefore, residential and occupational exposure risk assessments for the incidental oral, dermal, and inhalation exposure routes are not required.

>

<D. Cumulative Effects

>

EPA has not made a common mechanism of toxicity finding as to pyriofenone and any other substances, and pyriofenone does not appear to produce a toxic  metabolite produced by other substances. For the purposes of this tolerance action, therefore, EPA has not assumed that pyriofenone has a common mechanism of toxicity with other substances.

<E. Safety Determination>

B*

B*

B*

!

"

(

C

E

u

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

B*

Based on the completeness and reliability of the toxicity data and the conservative exposure assessments, there is a reasonable certainty that no harm will result to infants and children from the aggregate exposure of residues of pyriofenone.>

<F. International Tolerances>

<Presently, there are no Codex maximum residue levels (MRLs) established for residues of pyriofenone on any crop.  >

 PAGE

 PAGE   2


[Federal Register Volume 80, Number 74 (Friday, April 17, 2015)]
[Notices]
[Page 21236]
[FR Doc No: 2015-08879]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 13213-003; Project No. 13214-003]

Lock 14 Hydro Partners; Lock 12 Hydro Partners; Notice of
Technical Meeting

    a. Project Names and Numbers: From upstream to downstream order,
Heidelberg Hydroelectric Project No. 13213, and Ravenna Hydroelectric
Project No. 13214.
    b. Date and Time of Meeting: April 28, 2015; 10:00 p.m. Eastern
Time (11:00 p.m. Central Time).
    c. FERC Contact: Michael Spencer<EMAIL_ADDRESS>or (202)
502-6093.
    d. Purpose of Meeting: To discuss the concerns raised in the FWS
letter, filed March 31, 2015, about endangered species for the projects
listed above.
    e. A summary of the meeting will be prepared and filed for the
projects' records.
    f. All local, state, and federal agencies, Indian tribes, and other
interested parties are invited to participate by phone. Please contact
Michael Spencer at<EMAIL_ADDRESS>or<PHONE_NUMBER> by close
of business Tuesday, November 25, 2014, to R.S.V.P. and to receive
specific instructions on how to participate.

    Dated: April 13, 2015.
Kimberly D. Bose,
Secretary.
[FR Doc. 2015-08879 Filed 4-16-15; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register: June 12, 2008 (Volume 73, Number 114)]
[Rules and Regulations]
[Page 33296-33297]
[DOCID:fr12jn08-6]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2007-0278; Airspace Docket No. 07-AEA-18]

Establishment of Class E Airspace; Cranberry Township, PA

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule, confirmation of effective date.

-----------------------------------------------------------------------

SUMMARY: This action confirms the effective date of a direct final rule
that establishes Class E Airspace at Cranberry Township, PA, to support
a new Area Navigation (RNAV) Global Positioning System (GPS) Special
Instrument Approach Procedure (IAP) that has been developed for medical
flight operations into the University of Pittsburgh Medical Center
(UPMC) Passavant-Cranberry Heliport. Additionally, this action corrects
a minor typing error in the publication of the coordinates for the UPMC
Passavant-Cranberry Heliport.

DATES: Effective 0901 UTC, June 5, 2008. The Director of the Federal
Register approves this incorporation by reference action under title 1,
Code of Federal Regulations, part 51, subject to the annual revision of
FAA Order 7400.9 and publication of conforming amendments.

FOR FURTHER INFORMATION CONTACT: Melinda Giddens, System Support Group,
Eastern Service Center, Federal Aviation Administration, P.O. Box
20636, Atlanta, Georgia 30320; telephone<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Confirmation of Effective Date

    The FAA published this direct final rule with a request for
comments in the Federal Register on February 14, 2008 (73 FR 8597), to
establish Class E airspace at Cranberry Township, PA. The FAA uses the
direct final rulemaking procedure for a non-controversial rule where
the FAA believes that there will be no adverse public comment. This
direct final rule advised the public that no adverse

comments were anticipated, and that unless a written adverse comment,
or a written notice of intent to submit such an adverse comment, were
received within the comment period, the regulation would become
effective on June 5, 2008. No adverse comments were received, and thus
this notice confirms that effective date.

Correction to Final Rule

0
After publication, it was discovered that the airport reference point
of the University of Pittsburgh Medical Center (UPMC) Passavant-
Cranberry Heliport was incorrectly published as lat. 40[deg]41'01'' N.,
long. 80[deg]05'50'' W. The coordinates are corrected as follows,
``lat. 40[deg]41'02'' N., long. 80[deg]05'47'' W.''
0
Accordingly, pursuant to the authority delegated to me, the coordinates
for UPMC Passavant-Cranberry Heliport, Cranberry Township, PA, as
published in the Federal Register on February 14, 2008 (73 FR 8597),
Federal Docket No. FAA-2007-0278 is corrected as follows:

Sec.  71.1  [Corrected]

    On page 8597, replace

    ``(Lat. 40[deg]41'01'' N., long. 80[deg]05'50'' W.)

with

    ``(Lat. 40[deg]41'02'' N., long. 80[deg]05'47'' W.)

    Issued in College Park, Georgia, on April 30, 2008.
Mark D. Ward,
Manager, Operations Support Group Eastern Service Center, Air Traffic
Organization.
 [FR Doc. E8-12781 Filed 6-11-08; 8:45 am]

BILLING CODE 4910-13-M


[Federal Register Volume 78, Number 247 (Tuesday, December 24, 2013)]
[Notices]
[Pages 77689-77690]
[FR Doc No: 2013-30580]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0001]

Orthopaedic and Rehabilitation Devices Panel of the Medical
Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
    Name of Committee: Orthopaedic and Rehabilitation Devices Panel of
the Medical Devices Advisory Committee.
    General Function of the Committee: To provide advice and
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on February 21, 2014, from
8 a.m. to 3 p.m.
    Location: Hilton Washington DC North/Gaithersburg, Salons A, B, C
and D, 620 Perry Pkwy., Gaithersburg, MD 20877. The hotel's telephone
number is<PHONE_NUMBER>.
    Contact Person: Sara Anderson, Center for Devices and Radiological
Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
66, rm. 1643, Silver Spring, MD 20993-0002<EMAIL_ADDRESS>
301-796-7047, or FDA Advisory Committee Information Line, 1-800-741-
8138<PHONE_NUMBER> in the Washington, DC area). A notice in the Federal
Register about last minute modifications that impact a previously
announced advisory committee meeting cannot always be published quickly
enough to provide timely notice. Therefore, you should always check the
Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm
and scroll down to the appropriate advisory committee meeting link, or
call the advisory committee information line to learn about possible
modifications before coming to the meeting.
    Agenda: On February 21, 2014, the committee will discuss and make
recommendations regarding the 515(i) order issued by FDA on April 9,
2009 [Docket No. FDA-2009-M-0101], relating to the regulatory
classification of iontophoresis devices, one of the remaining
preamendments class III devices. Iontophoresis is a method of non-
invasive transdermal delivery in which a substance bearing a charge is
propelled through the skin by an electric current. Iontophoresis
devices generally consist of a controller, active and return
electrode(s), and power supply used to deliver currents to transport
drugs, soluble salts, or ionic solutions across the skin.
    The regulation for iontophoresis devices (21 CFR 890.5525)
currently has two parts. Part (a) of the regulation classifies
iontophoresis devices as class II when indicated to introduce drugs or
soluble salts to induce sweating for use in the diagnosis of cystic
fibrosis or for other uses if the drug intended for use with the device
bears adequate directions for the device's use with that drug. Devices
identified in part (a) of the regulation will not be considered in the
scope of the committee meeting. Part (b) of the regulation classifies
iontophoresis devices as class III when intended to use direct current
to introduce soluble salts or other drugs into the body for purposes
other than those specified in part (a). Devices identified in part (b)
of the regulation are the subject of the committee meeting.
    On August 28, 1979, FDA published a proposed rule (44 FR 50520) for
classification of iontophoresis devices for specialized uses (for the
diagnosis of cystic fibrosis, fluoride uptake acceleration in
dentistry, and for local anesthesia of the intact tympanic membrane)
into class II and for all other uses into class III. FDA recommended
class III for iontophoresis devices when used for purposes other than
those specifically considered because such use presents ``a potential
unreasonable risk of injury without benefit to the patient because
substantial data and clinical investigations do not exist to support
the claims made for the devices.'' In addition, the Agency noted that
insufficient information exists to determine that general controls
would provide reasonable assurance of the safety and effectiveness of
the device and that insufficient information exists to establish a
performance standard to provide this assurance.
    Subsequent to the proposed rule, FDA published a final rule (48 FR
53047) on November 23, 1983, classifying iontophoresis devices for use
in the diagnosis of cystic fibrosis or other uses if the labeling of
the drug intended for use with the device bears adequate directions for
the device's use with that drug as class II (performance standards)

and iontophoresis devices intended for any other purposes as class III
(premarket approval). The final rule was issued after consideration of
three comments submitted in response to the 1979 proposed rule that
disagreed with the proposal classifying into class III iontophoresis
devices for uses other than diagnosing cystic fibrosis, application of
fluoride in dentistry, or anesthetizing the tympanic membrane. Based on
FDA's analysis of the available literature and input from the Physical
Medicine; Ear, Nose and Throat; and Dental Device Classification Panels
(see the preamble to the proposed rule 44 FR 50520), FDA disagreed with
the comments and concluded that insufficient data exist to support uses
of the device other than those specifically considered. In addition,
the final rule removed the dental application of fluoride and local
anesthesia of the intact tympanic membrane uses from the class II
definition because it was determined that there were no marketed drugs
with adequate instructions for use with an iontophoresis device for
these uses. The effect of this change in the identification was to
classify into class III iontophoresis devices for these two uses.
    In 1987, FDA published a clarification by inserting language in the
codified language stating that no effective date had been established
for the requirement for premarket approval for iontophoresis devices
intended for any other purposes (52 FR 17742, May 11, 1987).
    On August 22, 2000, FDA published a proposed rule (65 FR 50949) to
amend the iontophoresis device regulation to remove the class III
(premarket approval) identification because FDA believed there were no
preamendments iontophoresis devices marketed for uses other than those
described in the class II identification. The proposed rule stated that
manufacturers of iontophoresis devices that had been cleared as class
III 510(k)s could revise the labeling of their devices to meet the
class II identification.
    On November 4, 2004, FDA withdrew the proposed rule issued on
August 22, 2000 (65 FR 50949), in response to comments received (69 FR
64266). FDA simultaneously issued a Notice of Intent to reclassify
iontophoresis devices currently in class III into class II (special
controls) and provided an opportunity for interested persons to submit
any new information concerning the safety and effectiveness of
iontophoresis devices (69 FR 64313). FDA did not take further
regulatory action regarding iontophoresis devices prior to issuing the
2009 515(i) order on April 9, 2009 [Docket No. FDA-2009-M-0101],
relating to their regulatory classification.
    The discussion at the committee meeting will involve making
recommendations regarding regulatory classification to either reconfirm
to class III (subject to PMA), or reclassify to class I or class II
(subject to 510(k)). The committee will further be asked to comment on
whether general and/or special controls are adequate to reasonably
ensure the safety and effectiveness of the device and whether, if
reclassified to Class II, these devices should be exempt from premarket
notification requirements.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
January 31, 2014. Oral presentations from the public will be scheduled
between approximately 10:45 a.m. and 11:45 a.m. on February 21, 2014.
Those individuals interested in making formal oral presentations should
notify the contact person and submit a brief statement of the general
nature of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
January 23, 2014. Time allotted for each presentation may be limited.
If the number of registrants requesting to speak is greater than can be
reasonably accommodated during the scheduled open public hearing
session, FDA may conduct a lottery to determine the speakers for the
scheduled open public hearing session. The contact person will notify
interested persons regarding their request to speak by January 24,
2014.
    Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact AnnMarie Williams at
<EMAIL_ADDRESS>301-796-5966, at least 7 days in advance
of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: December 17, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2013-30580 Filed 12-23-13; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register Volume 78, Number 213 (Monday, November 4, 2013)]
[Notices]
[Page 66098]
[FR Doc No: 2013-26340]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Air Traffic Procedures Advisory Committee

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of Meeting

-----------------------------------------------------------------------

SUMMARY: The FAA is issuing this notice to advise the public that a
meeting of the Federal Aviation Administration Air Traffic Procedures
Advisory Committee (ATPAC) will be held to review present air traffic
control procedures and practices for standardization, revision,
clarification, and upgrading of terminology and procedures.

DATES: The meeting will be held Tuesday, December 17, and Wednesday,
December 18, 2013, from 8:30 a.m. to 5:00 p.m.

ADDRESSES: The meeting will be held at CGH Technologies, Inc., 600
Maryland Ave. SW., Suite 800W, Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT: Mr. Gary Norek, ATPAC Executive
Director, 800 Independence Avenue SW., Washington, DC 20591.

SUPPLEMENTARY INFORMATION: Pursuant to Section 10(a)(2) of the Federal
Advisory Committee Act (Pub. L. 92-463; 5 U.S.C. App. 2), notice is
hereby given of a meeting of the ATPAC to be held Tuesday, December 17,
and Wednesday, December 18, 2013, from 8:30 a.m. to 5:00 p.m.
    The agenda for this meeting will cover a continuation of the
ATPAC's review of present air traffic control procedures and practices
for standardization, revision, clarification, and upgrading of
terminology and procedures. It will also include:
    1. Approval of Minutes;
    2. Submission and Discussion of Areas of Concern;
    3. Discussion of Potential Safety Items;
    4. Report from Executive Director;
    5. Items of Interest; and
    6. Discussion and agreement of location and dates for subsequent
meetings.
    Attendance is open to the interested public but limited to space
available. With the approval of the Chairperson, members of the public
may present oral statements at the meeting. Persons desiring to attend
and persons desiring to present oral statement should notify Mr. Gary
Norek no later than Friday, November 22, 2013. Any member of the public
may present a written statement to the ATPAC at any time at the address
given above.

    Issued in Washington, DC, on October 25, 2013.
Gary A. Norek,
Executive Director, Air Traffic Procedures Advisory Committee.
[FR Doc. 2013-26340 Filed 11-1-13; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 79, Number 145 (Tuesday, July 29, 2014)]
[Notices]
[Page 44027]
[FR Doc No: 2014-17813]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER14-2465-000]

RE Columbia Two LLC; Supplemental Notice That Initial Market-
Based Rate Filing Includes Request for Blanket Section 204
Authorization

    This is a supplemental notice in the above-referenced proceeding of
RE Columbia Two LLC's application for market-based rate authority, with
an accompanying rate tariff, noting that such application includes a
request for blanket authorization, under 18 CFR Part 34, of future
issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street NE., Washington,
DC 20426, in accordance with Rules 211 and 214 of the Commission's
Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Anyone
filing a motion to intervene or protest must serve a copy of that
document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR Part 34, of future issuances of securities and assumptions of
liability, is August 12, 2014.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically should submit an original and
5 copies of the intervention or protest to the Federal Energy
Regulatory Commission, 888 First Street NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in
the Commission's eLibrary system by clicking on the appropriate link in
the above list. They are also available for review in the Commission's
Public Reference Room in Washington, DC. There is an eSubscription link
on the Web site that enables subscribers to receive email notification
when a document is added to a subscribed docket(s). For assistance with
any FERC Online service, please email<EMAIL_ADDRESS>or
call<PHONE_NUMBER> (toll free). For TTY, call<PHONE_NUMBER>.

    Dated: July 23, 2014.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2014-17813 Filed 7-28-14; 8:45 am]
BILLING CODE 6717-01-P